Halozyme Therapeutics acquires Elektrofi for $750 million, enhancing drug delivery technology with Hypercon's innovative ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the ...

Biocon inks deal with Amgen to market Bosaya & Aukelso biosimilars (Prolia & Xgeva copies) in the US from Oct 2025.

Bengaluru: Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...

Biocon Biologics, subsidiary of Biocon, announced a settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya (denosumab-kyqq) and Aukelso ...

Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Guselkumab is the first IL-23 inhibitor approved for pediatric plaque psoriasis and active psoriatic arthritis, addressing a significant treatment gap. The PROTOSTAR study showed 56% of children on ...

By ensuring timely wound care, vaccination, immunoglobulin administration, and responsible interaction with animals, rabies ...